Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2010-01-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
NCT02197286
Role of Vitamin D Supplementation in Schizophrenia
NCT03101319
Vitamin D for Schizophrenia
NCT01759485
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
NCT03284294
Plan D- Vitamin D Supplementation in Psychotic Disorders
NCT05211635
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immediate Vitamin D3
Will start Vitamin D3 immediately
Vitamin D3
Vitamin D3 50,000 units weekly
Three month delay
Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
Vitamin D3
50,000 units of Vitamin D3 weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D3
50,000 units of Vitamin D3 weekly
Vitamin D3
Vitamin D3 50,000 units weekly
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Schizophrenia or Schizoaffective disorder
* stabilized but not expecting to be discharged soon
* capacity to give informed consent
Exclusion Criteria
* acutely medically ill
* renal insufficiency
* hypercalcemia
* hyperparathyroidism
19 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bronx Psychiatric Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nigel Bark MD
Director of Scizhophrenia Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NIgel Bark, MD
Role: PRINCIPAL_INVESTIGATOR
Bronx Psychiatric Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bronx Psychiatric Center
The Bronx, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BPCIRB0804
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.